{"gene":"PARN","run_date":"2026-06-10T05:19:53","timeline":{"discoveries":[{"year":2005,"finding":"Crystal structure of C-terminal truncated human PARN in free and RNA-bound forms reveals a homodimer with an R3H domain and a nuclease domain; the R3H domain of one subunit partially encloses the active site of the other, poly(A) binds in a deep cavity in a sequence-nonspecific manner, and mutations disrupting dimerization abolish both enzymatic and RNA-binding activities, establishing the dimer as the structural and functional unit. The cap-binding domain acts with the R3H domain to amplify processivity.","method":"X-ray crystallography (free and RNA-bound forms) combined with dimerization-disrupting mutagenesis and enzymatic activity assays","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure with functional mutagenesis validating dimerization requirement for catalysis","pmids":["16281054"],"is_preprint":false},{"year":2001,"finding":"Xenopus PARN (xPARN) is a poly(A)-specific 3' exonuclease that copurifies as 62 kDa and 74 kDa polypeptides (the 62 kDa being a proteolytic product). It contains a tripartite exonuclease domain, a putative RNA recognition motif, and an MCM-like domain. It can be activated in the oocyte nucleus independently of cytoplasmic components, and nuclear export of deadenylated RNA is impeded. The enzyme binds poly(A) in the absence of catalysis, contributing to substrate specificity.","method":"Protein purification, molecular cloning, in vitro deadenylation assay, microinjection into Xenopus oocytes, western blot","journal":"RNA (New York, N.Y.)","confidence":"High","confidence_rationale":"Tier 1 / Moderate — biochemical reconstitution with in vitro assay plus in vivo microinjection; single lab but multiple orthogonal methods","pmids":["11424938"],"is_preprint":false},{"year":2006,"finding":"CUG-BP (CUGBP1) binds ARE-containing mRNAs (c-fos, TNFα) and directly recruits PARN deadenylase to stimulate poly(A) shortening. CUG-BP interacts with PARN in cell extracts by co-immunoprecipitation, and this interaction is recapitulated with recombinant proteins, identifying CUG-BP as the first RNA-binding protein shown to directly recruit a deadenylase to an RNA substrate.","method":"In vitro deadenylation assay, co-immunoprecipitation from extracts, recombinant protein pulldown","journal":"RNA (New York, N.Y.)","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — in vitro reconstitution of recruitment plus reciprocal co-IP with recombinant proteins, single lab","pmids":["16601207"],"is_preprint":false},{"year":2012,"finding":"PARN knockdown in human cells causes accumulation of oligoadenylated processing intermediates of H/ACA box snoRNAs and scaRNAs (but not C/D box RNAs). PARN is concentrated in nucleoli and Cajal bodies. The non-canonical poly(A) polymerase PAPD5 adds oligo(A) tails to snoRNA 3' stubs, and PARN removes these tails to complete 3' end maturation, coupling deadenylation to clean trimming and snoRNA stabilization.","method":"siRNA knockdown, deep sequencing of RNA 3' ends, immunofluorescence localization, PAPD5 knockdown epistasis","journal":"RNA (New York, N.Y.)","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic epistasis (PARN + PAPD5 knockdown), 3'-end sequencing, and localization in single study with multiple orthogonal methods","pmids":["22442037"],"is_preprint":false},{"year":2015,"finding":"PARN is required for 3'-end maturation of the telomerase RNA component (TERC). Patient-derived cells with PARN mutations show decreased TERC levels and increased oligo(A)-tailed forms of TERC. Deep sequencing demonstrates that PARN removes post-transcriptionally acquired oligo(A) tails that target TERC for nuclear degradation. Restoring PARN normalizes TERC levels and the proportion of oligo(A) forms.","method":"Deep sequencing of TERC 3' ends in patient-derived somatic cells and iPSCs, PARN complementation rescue, PARN disruption in immortalized cells","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — replicated across patient-derived and engineered cell models with deep sequencing and rescue experiments","pmids":["26482878"],"is_preprint":false},{"year":2016,"finding":"PARN increases human telomerase RNA (hTR) levels by deadenylating hTR, thereby limiting its degradation by EXOSC10 (which is recruited following PAPD5-mediated oligoadenylation). Defects in dyskerin binding lead to hTR degradation via PAPD5 oligoadenylation → EXOSC10 3'-to-5' decay, as well as decapping by DCP2 and 5'-to-3' decay by XRN1. Knockdown of DCP2 and/or EXOSC10 rescues telomerase activity and hTR localization in PARN-deficient cells.","method":"Knockdown epistasis (PARN, PAPD5, EXOSC10, DCP2, XRN1), hTR level and localization measurements, telomerase activity assays","journal":"Nature structural & molecular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multi-component epistasis with multiple knockdowns and rescue, replicated across dyskerin- and PARN-deficient contexts","pmids":["26950371"],"is_preprint":false},{"year":2015,"finding":"PARN deadenylase activity is required for deadenylation of miR-122 in human cells; PARN knockdown leads to accumulation of 3'-oligoadenylated miR-122 and increased miR-122 stability. CUGBP1 specifically interacts with miR-122 and other UG-rich miRNAs, interacts directly with PARN, and recruits PARN to miR-122 to enhance PARN-mediated deadenylation and degradation in a dose-dependent manner in vitro.","method":"PARN knockdown, deep sequencing of miRNA 3' ends, in vitro deadenylation assay with CUGBP1, PARN/CUGBP1 co-immunoprecipitation","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — in vitro reconstitution of CUGBP1-stimulated PARN activity on miRNA plus cell-based knockdown with 3'-end sequencing","pmids":["26130707"],"is_preprint":false},{"year":2019,"finding":"PARN regulates the levels of numerous miRNAs by removing oligo(A) tails added by PAPD5; remaining oligo(A) tails recruit the exonucleases DIS3L or DIS3L2 to degrade the miRNA. PARN knockdown destabilizes multiple miRNAs that repress p53 translation, leading to p53 accumulation in a Dicer-dependent manner, explaining the p53 elevation in PARN-defective patients.","method":"PARN/PAPD5/DIS3L/DIS3L2 knockdown epistasis, miRNA 3'-end sequencing, p53 protein measurement, Dicer-dependence experiment","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — multi-component epistasis with multiple knockdowns and rescue across orthogonal methods in a single rigorous study","pmids":["30770239"],"is_preprint":false},{"year":2017,"finding":"PARN depletion reduces levels of abundant human Y RNAs. PAPD5 depletion or DIS3L knockdown rescues the effect of PARN depletion on Y RNA levels, establishing that PARN stabilizes Y RNAs by removing PAPD5-added oligoadenylated tails that otherwise recruit DIS3L for degradation. PARN also deadenylates U6 and RMRP RNAs without affecting their levels.","method":"PARN/PAPD5/DIS3L knockdown epistasis, deep sequencing of RNA 3' ends","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic epistasis with multiple knockdowns confirmed by 3'-end sequencing, single lab","pmids":["28760775"],"is_preprint":false},{"year":2018,"finding":"PARN and TOE1 act redundantly on small Cajal body-specific RNAs (scaRNAs) and on TERC biogenesis. Combined depletion of PARN and TOE1 strongly downregulates scaRNAs, leading to defects in snRNA pseudouridylation. Neither enzyme alone targets mRNA poly(A) tails; their substrates are nuclear small ncRNAs.","method":"mTAIL-seq, RNA-seq, double knockdown of PARN and TOE1, snRNA pseudouridylation assay","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Moderate — double-knockdown epistasis combined with genome-wide 3'-end sequencing and functional snRNA pseudouridylation readout","pmids":["29669292"],"is_preprint":false},{"year":2018,"finding":"TERC precursor processing by PARN and RRP6 occurs in two steps: longer 3'-extended precursors are first trimmed by RRP6, then shorter forms are processed by PARN. H/ACA RNP assembly actively promotes productive processing and protects the mature 3' end; tertiary RNA interactions in longer transcripts favor degradation over processing.","method":"In vitro RNA processing assays with purified PARN and RRP6, H/ACA RNP assembly assays, RNA structure probing","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with purified enzymes, RNP assembly assays, and structural analysis, single lab","pmids":["30575725"],"is_preprint":false},{"year":2016,"finding":"In C. elegans, PARN-1 (the PARN ortholog) trims piRNA 3' ends; PARN-1-deficient animals accumulate untrimmed piRNAs with 3' extensions. Longer piRNAs associate with the Piwi protein PRG-1 but fail to robustly recruit downstream silencing factors, demonstrating that precise piRNA length determined by PARN-1 is required for efficient transcriptome surveillance.","method":"PARN-1 loss-of-function genetics in C. elegans, deep sequencing of piRNAs, PRG-1 co-immunoprecipitation, silencing factor recruitment assay","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic loss-of-function in model organism with deep sequencing and biochemical validation of PRG-1 binding vs. silencing factor recruitment","pmids":["26919432"],"is_preprint":false},{"year":2015,"finding":"Cells from patients with biallelic PARN mutations have severely reduced PARN deadenylation activity and impaired oligoadenylation of specific H/ACA box snoRNAs. PARN-deficient patient cells display short telomeres and aberrant ribosome profiles. Knockdown of PARN in human marrow cells and zebrafish impairs haematopoiesis.","method":"Biochemical deadenylation activity assay on patient cells, snoRNA oligoadenylation analysis, telomere length measurement, ribosome profile, PARN knockdown in human marrow cells and zebrafish morpholino experiments","journal":"Journal of medical genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (biochemical, cell biology, in vivo model) in single study; patient cell findings replicated in zebrafish model","pmids":["26342108"],"is_preprint":false},{"year":2012,"finding":"PARN knockdown in mouse myoblasts stabilizes a defined set of ~40 mRNAs including ZFP36L2, and increases Zfp36l2 poly(A) tail length and translation. The PARN-dependent regulatory elements reside in the 3' UTR. PARN knockdown also broadly affects gene expression, reducing levels of mRNAs encoding cell migration and adhesion factors; PARN-depleted cells migrate faster in wound-healing assays.","method":"Stable PARN knockdown, global mRNA half-life analysis, poly(A) tail length assay, 3' UTR reporter assay, wound-healing migration assay","journal":"PLoS genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genome-wide mRNA stability analysis plus mechanistic 3' UTR reporter and functional migration assay, single lab","pmids":["22956911"],"is_preprint":false},{"year":2016,"finding":"Molecular recognition of the mRNA 5' cap by PARN differs from other cap-binding proteins: PARN dimer subunits show negative cooperativity in cap binding; non-coulombic interactions dominate complex formation; and PARN has versatile activity toward alternative cap forms. Cap binding amplifies the processivity of PARN deadenylation.","method":"Surface plasmon resonance kinetics, quantitative equilibrium fluorescence titrations, circular dichroism","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — multiple biophysical methods (SPR, fluorescence titration, CD) in single lab establishing cap-binding mechanism","pmids":["26772900"],"is_preprint":false},{"year":2019,"finding":"The intrinsically disordered C-terminal domain (CTD) of PARN contains nuclear and nucleolar localization signals. Phosphorylation-mimic mutation S557D disrupts local CTD structure and alters binding partner selection: under normal conditions nucleolus-residing PARN recruits CBP80 to repress deadenylase activity; DNA damage-induced phosphorylation of S557 expels CBP80 from nucleoli (releasing activity inhibition) and recruits CstF-50 into nucleoli to activate deadenylation. This function switch reshapes the profile of small nuclear ncRNAs in response to DNA damage.","method":"Mutagenesis (S557D phospho-mimic), spectroscopic analysis of CTD structure, fluorescence microscopy of protein localization, co-immunoprecipitation of CBP80 and CstF-50, ncRNA profiling","journal":"Cells","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — phospho-mimic mutagenesis combined with localization imaging and co-IP identifying distinct partners, single lab","pmids":["31387300"],"is_preprint":false},{"year":2015,"finding":"PARN is a phosphoprotein and its phosphorylation state is modulated by serum status. Under serum deprivation, cap association by PARN increases while eIF4E cap occupancy decreases, suggesting a competition at the 5' cap regulated by post-translational phosphorylation of PARN that influences whether mRNA is translated or decayed.","method":"Cap-binding fractionation assay, phosphoprotein analysis, serum starvation treatment, reporter translation assay","journal":"Nucleic acids research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct cap-binding and phosphorylation measurements under defined conditions, single lab, multiple methods","pmids":["15653638"],"is_preprint":false},{"year":2015,"finding":"PARN mediates miRNA-dependent degradation of TP53 mRNA. Argonaute-2 (Ago-2), the core component of miRISC, co-exists in complexes with PARN and activates its deadenylase activity. miR-125b-loaded miRISC recruits PARN to TP53 mRNA via both an ARE and an adjacent miR-125b/miR-504 targeting site in the 3' UTR; HuR can revert this recruitment.","method":"Co-immunoprecipitation of Ago-2 with PARN, in vitro deadenylase activity assay, 3' UTR reporter assays, PARN knockdown mRNA stability measurement","journal":"Nucleic acids research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP of PARN-Ago2 complex plus in vitro activity and 3' UTR reporter, single lab","pmids":["26400160"],"is_preprint":false},{"year":2017,"finding":"Nucleolin (NCL) phosphorylation at CK2 consensus sites is required to activate PARN deadenylase activity upon oncogenic stimuli and UV stress. NCL interacts directly with PARN and, under non-stress conditions, forms complexes with p53 and HuR. Phosphorylation-deficient NCL (NCL-6/S*A) cannot activate PARN, and hypophosphorylated NCL favors interactions with HuR and p53. NCL interacts with PARN substrate mRNAs including TP53 and BCL2.","method":"Co-immunoprecipitation of NCL with PARN, deadenylase activity assay with WT vs. phospho-deficient NCL, UV stress treatment, mRNA stability measurement","journal":"RNA biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct binding assay plus functional deadenylase activity with phospho-mutant, single lab","pmids":["29168431"],"is_preprint":false},{"year":2014,"finding":"PARN can self-associate into tetramers and higher-order oligomers both in vitro and in living cells. Self-association is triggered by the R3H domain, which causes burial of Trp219 in a solvent-inaccessible environment. The RRM and C-terminal domains modulate the dissociation rate of tetrameric PARN. Tetramerization significantly enhances the catalytic activity and processivity of the truncated form lacking the RRM and C-terminal domains.","method":"Analytical ultracentrifugation/size-exclusion chromatography for oligomerization, site-directed mutagenesis of R3H domain, tryptophan fluorescence spectroscopy, in vitro deadenylase activity assay of truncations","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro biochemical reconstitution with mutagenesis and enzymatic assay, single lab","pmids":["25239613"],"is_preprint":false},{"year":2019,"finding":"PARN deficiency compromises ribosomal RNA biogenesis in patient fibroblasts and heterozygous Parn knockout mice. PARN deficiency down-regulates shelterin transcripts (TRF1, TRF2, TPP1, RAP1, POT1) and DKC1 mRNA (the latter through p53 activation). Homozygous Parn KO causes early embryonic lethality not rescued by p53 KO.","method":"Patient fibroblast analysis, inducible PARN KO and complementation cell line, heterozygous Parn KO mice, rRNA biogenesis assay, RT-qPCR for shelterin transcripts, double Parn/p53 KO","journal":"EMBO molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple model systems (patient cells, KO mouse, inducible KO cell line), single lab, but mechanisms partially inferred from expression data","pmids":["31273937"],"is_preprint":false},{"year":2020,"finding":"PARN is anchored to the endoplasmic reticulum (ER) surface where it reshapes the poly(A) length profile of ER-associated RNAs by suppressing long poly(A) tails. ER-anchored PARN triggers degradation of a subset of ER-enriched transcripts including MDM2, modulating DNA damage response and cell viability. MK2 kinase phosphorylates PARN-Ser557 during DNA damage to promote PARN translocation from the ER to the cytosol.","method":"Subcellular fractionation, liposome insertion assay with purified PARN, ER-anchored PARN expression constructs, transcriptome sequencing of ER-associated RNAs, MK2 kinase phosphorylation assay, poly(A) tail length analysis","journal":"Cells","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — biochemical reconstitution of membrane insertion plus cell-based fractionation and functional transcriptomics, single lab","pmids":["31936572"],"is_preprint":false},{"year":2009,"finding":"Synthetic fluoro-pyranosyl nucleoside analogues (cytosine- and adenine-based) competitively inhibit human PARN at its active site. Kinetic analysis shows the inhibition is competitive and cannot be released by altering Mg²⁺ concentration. Molecular docking indicates the sugar moiety stabilizes the compounds in the active site through interactions with catalytic residues.","method":"In vitro PARN deadenylase activity kinetic analysis, molecular docking and molecular dynamics simulation","journal":"Biochemistry","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro kinetic analysis with defined mechanism plus computational docking, single lab","pmids":["19472977"],"is_preprint":false},{"year":2011,"finding":"Novel uracil-based glucopyranosyl nucleoside analogues (including U1) inhibit human PARN via slow-binding, slow-release competitive inhibition at the active site, with Ki values in the low µM range (11–33-fold lower than previously reported adenosine/cytosine analogues). Molecular docking confirms binding at the PARN active site.","method":"In vitro kinetic analysis (slow-binding inhibition kinetics), molecular docking","journal":"Biochimie","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — detailed kinetic mechanism with slow-binding analysis plus docking, single lab","pmids":["22041582"],"is_preprint":false},{"year":2009,"finding":"Purine nucleotides inhibit human PARN in vitro: RTP nucleotides act as non-competitive inhibitors, while RDP and RMP exhibit competitive inhibition. Mg²⁺ can release inhibition by RTP and RDP but not RMP.","method":"In vitro PARN deadenylase activity kinetic analysis with varied Mg²⁺","journal":"Journal of enzyme inhibition and medicinal chemistry","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — rigorous kinetic analysis but single lab, single method, in vitro only","pmids":["18763168"],"is_preprint":false},{"year":2024,"finding":"PARN interacts with polypyrimidine tract-binding protein 1 (PTBP1) in pancreatic β cells, co-regulating the RNA stability of Slc30a8 and Chst3 mRNAs. PARN deficiency in β cells impairs glucose-stimulated insulin secretion (GSIS) and insulin maturation; conditional PARN knockout mice show reduced GSIS without altered β-cell development or insulin sensitivity.","method":"β-cell-specific conditional Parn KO mice, co-immunoprecipitation of PARN with PTBP1, LACE-seq for RNA-protein interactions, NIT-1 cell knockdown, glucose-stimulated insulin secretion assay, transcriptomics","journal":"Advanced science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional KO model combined with co-IP and RNA-protein interaction sequencing, single lab","pmids":["39297407"],"is_preprint":false},{"year":2023,"finding":"In glioblastoma stem cells, PARN positively regulates EGFR expression by negatively regulating the EGFR-targeting miRNA miR-7 through its 3'-5' exoribonuclease activity. Increased EGFR then creates a positive feedback loop activating STAT3, which transcriptionally drives PARN expression. PARN depletion in GSCs reduces tumor infiltration and prolongs survival in orthotopic xenografts.","method":"PARN knockdown (siRNA, shRNA), miR-7 level measurement, EGFR/STAT3 signaling assays, orthotopic brain tumor xenograft survival, pharmacological STAT3 inhibition, siRNA nanocapsule delivery","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function with in vivo xenograft and signaling epistasis, single lab","pmids":["37747775"],"is_preprint":false},{"year":2026,"finding":"PARN binds 3' UTRs and promotes utilization of proximal poly(A) sites genome-wide in B cells in vivo, binding UGUA and AA(U/A)AAA upstream elements to form a specific spatial RNA-protein complex. Through its exonuclease activity, PARN shortens poly(A) tails to decrease mRNA stability of targets including Foxp1, thereby promoting antibody secretion and class switch recombination.","method":"Conditional B-cell PARN knockout, genome-wide poly(A) site sequencing, RNA immunoprecipitation for binding elements, poly(A) tail length analysis, antibody secretion assay","journal":"Advanced science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional KO with genome-wide poly(A) site sequencing and functional antibody secretion readout, single lab","pmids":["42118147"],"is_preprint":false},{"year":2026,"finding":"PARN associates with pri-miR-29a and pri-miR-1207 and regulates their poly(A) tail lengths. CPSF6 recruits PARN to pri-miRNAs, and together they affect primary and mature miR-29a-3p levels. miR-29a-3p and miR-1207-5p in turn bind the 3' UTR of PARN mRNA to regulate its expression, establishing a mutual feedback regulatory loop. Modulation of PARN, miR-29a-3p, or miR-1207-5p expression affects cell migration.","method":"RNA immunoprecipitation of PARN with pri-miRNAs, CPSF6 co-immunoprecipitation, 3' UTR reporter for PARN mRNA, miRNA 3'-end sequencing, migration assay","journal":"Life science alliance","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — RNA-IP plus reporter assays plus functional migration readout, single lab","pmids":["41825960"],"is_preprint":false}],"current_model":"PARN is a divalent metal ion-dependent, poly(A)-specific 3'-to-5' exoribonuclease that functions as an obligate homodimer (with dimerization required for activity) and simultaneously engages the mRNA 5' cap (via its cap-binding domain) and the 3' poly(A) tail to processively deadenylate mRNAs; it also localizes to nucleoli and Cajal bodies where it removes PAPD5-added oligo(A) tails from H/ACA snoRNAs, scaRNAs, TERC, Y RNAs, and certain miRNAs—preventing their degradation by EXOSC10 and DIS3L/DIS3L2—and its activity is regulated by phosphorylation (e.g., MK2-mediated Ser557 phosphorylation that shifts PARN from ER to cytosol or expels CBP80 from the nucleolus to relieve inhibition), by RNA-binding protein co-factors (CUG-BP/CUGBP1, nucleolin, Ago2-miRISC) that recruit it to specific substrates, and by its own oligomerization state, collectively controlling mRNA stability, ncRNA maturation, telomere maintenance, ribosome biogenesis, and p53 levels."},"narrative":{"mechanistic_narrative":"PARN is a divalent metal ion-dependent, poly(A)-specific 3'-to-5' exoribonuclease that controls the stability and 3'-end maturation of both mRNAs and small noncoding RNAs [PMID:16281054, PMID:11424938, PMID:22442037]. Structurally it functions as an obligate homodimer in which the R3H domain of one subunit partially encloses the catalytic site of the other, and disrupting dimerization abolishes both nuclease and RNA-binding activity [PMID:16281054]; the enzyme can further self-associate into tetramers and higher-order oligomers that enhance catalytic processivity [PMID:25239613]. PARN simultaneously engages the substrate 3' poly(A) tail and the mRNA 5' cap, and cap binding amplifies its processive deadenylation [PMID:16281054, PMID:26772900, PMID:15653638]. In the nucleolus and Cajal bodies, PARN performs maturation trimming by removing oligo(A) tails that the noncanonical poly(A) polymerase PAPD5 adds to H/ACA box snoRNAs, scaRNAs, the telomerase RNA TERC/hTR, and Y RNAs; without PARN these oligoadenylated species are diverted to exonucleolytic destruction by EXOSC10/RRP6 or DIS3L/DIS3L2, so PARN stabilizes these RNAs by preventing their degradation [PMID:22442037, PMID:26482878, PMID:26950371, PMID:28760775, PMID:30575725]. Through analogous removal of PAPD5-added oligo(A) tails, PARN also destabilizes specific miRNAs, including a set that represses p53 translation, so that PARN loss elevates p53 in a Dicer-dependent manner [PMID:30770239]. PARN substrate selection is directed by RNA-binding cofactors—CUGBP1, nucleolin, Ago2-miRISC, PTBP1, and CPSF6—that recruit it to defined transcripts such as c-fos, TNFα, miR-122, and TP53 mRNA [PMID:16601207, PMID:26130707, PMID:26400160, PMID:29168431, PMID:39297407, PMID:41825960], and its activity is gated by phosphorylation, including DNA-damage/MK2-driven Ser557 phosphorylation that switches its localization and partner selection between the nucleolus, ER, and cytosol [PMID:31387300, PMID:31936572]. Biallelic PARN mutations reduce deadenylase activity, shorten telomeres, and perturb snoRNA processing and ribosome biogenesis, with effects on hematopoiesis and embryonic development [PMID:26342108, PMID:31273937].","teleology":[{"year":2001,"claim":"Established that PARN is a poly(A)-specific 3' exonuclease whose poly(A) binding contributes to substrate specificity and that can act in the nucleus, defining the basic enzymatic identity.","evidence":"Protein purification, in vitro deadenylation, and Xenopus oocyte microinjection of xPARN","pmids":["11424938"],"confidence":"High","gaps":["Structural basis of poly(A) recognition not yet resolved","Human enzyme regulation not addressed"]},{"year":2005,"claim":"Resolved how PARN catalysis works structurally, showing the active unit is a homodimer in which the R3H domain of one subunit engages the partner active site and cap binding amplifies processivity.","evidence":"X-ray crystallography of free and RNA-bound truncated human PARN plus dimerization-disrupting mutagenesis","pmids":["16281054"],"confidence":"High","gaps":["C-terminal domain absent from crystallized construct","Cap-binding domain mechanism not directly visualized"]},{"year":2006,"claim":"Answered how PARN is targeted to specific mRNAs, identifying CUGBP1 as the first RNA-binding protein that directly recruits a deadenylase to ARE-containing substrates.","evidence":"In vitro deadenylation, co-IP from extracts, and recombinant protein pulldown on c-fos/TNFα mRNAs","pmids":["16601207"],"confidence":"High","gaps":["In vivo significance of CUGBP1 recruitment not established","Generality across other ARE mRNAs untested"]},{"year":2012,"claim":"Extended PARN's role from mRNA decay to noncoding RNA maturation, showing it trims PAPD5-added oligo(A) tails to complete 3'-end maturation of H/ACA snoRNAs and scaRNAs in nucleoli and Cajal bodies.","evidence":"siRNA knockdown with 3'-end deep sequencing, immunofluorescence, and PAPD5 epistasis; parallel mouse myoblast mRNA stability/migration study","pmids":["22442037","22956911"],"confidence":"High","gaps":["Why C/D box snoRNAs are spared not explained","Direct enzyme-substrate kinetics in vivo not measured"]},{"year":2015,"claim":"Connected PARN to telomere biology and disease by showing it matures TERC by removing oligo(A) tails, with patient mutations reducing TERC and shortening telomeres while broadening the miRNA/mRNA targets directed by CUGBP1 and miRISC.","evidence":"TERC 3'-end sequencing in patient cells with complementation rescue; PARN/CUGBP1 reconstitution on miR-122; Ago2-PARN co-IP and TP53 3'-UTR reporters; patient cell activity assays with zebrafish/marrow knockdown","pmids":["26482878","26130707","26400160","26342108"],"confidence":"High","gaps":["Causal chain from TERC defect to specific clinical phenotypes incompletely mapped","Several cofactor recruitment events from single labs"]},{"year":2016,"claim":"Defined the degradation pathways PARN protects against, showing PARN-mediated deadenylation of hTR limits PAPD5-EXOSC10 decay and decapping/XRN1 routes, and characterized the cap-binding mechanism biophysically.","evidence":"Multi-component knockdown epistasis (PAPD5, EXOSC10, DCP2, XRN1) with telomerase assays; SPR/fluorescence/CD cap-binding kinetics","pmids":["26950371","26772900"],"confidence":"High","gaps":["Stoichiometry of competing decay enzymes in cells not quantified","Physiological cap forms engaged in vivo unclear"]},{"year":2017,"claim":"Broadened the noncoding RNA target set and revealed cofactor-controlled activation, establishing Y RNA stabilization via PAPD5/DIS3L and nucleolin phosphorylation as an activating switch for PARN.","evidence":"PARN/PAPD5/DIS3L knockdown epistasis with 3'-end sequencing; NCL-PARN co-IP and deadenylase assays with phospho-deficient NCL under UV stress","pmids":["28760775","29168431"],"confidence":"Medium","gaps":["Single-lab findings without reciprocal validation","Kinase responsible for NCL phosphorylation in this context not pinned down"]},{"year":2018,"claim":"Clarified the division of labor among nuclear trimming enzymes, showing PARN acts redundantly with TOE1 on scaRNAs/TERC and works downstream of RRP6 in a two-step TERC processing pathway guided by H/ACA RNP assembly.","evidence":"PARN/TOE1 double knockdown with mTAIL-seq and snRNA pseudouridylation; in vitro processing with purified PARN and RRP6 plus RNP assembly and structure probing","pmids":["29669292","30575725"],"confidence":"High","gaps":["Determinants partitioning a precursor to processing vs degradation only partly defined","Redundancy quantification incomplete"]},{"year":2019,"claim":"Linked PARN to p53 control and organismal phenotypes, showing it destabilizes p53-repressing miRNAs via DIS3L/DIS3L2, that a phospho-mimic C-terminal switch reshapes nucleolar partner selection, and that PARN loss impairs rRNA biogenesis with embryonic lethality in mice.","evidence":"PARN/PAPD5/DIS3L/DIS3L2 knockdown with miRNA sequencing and Dicer-dependence; S557D mutagenesis with CTD spectroscopy, imaging, and CBP80/CstF-50 co-IP; patient fibroblasts, heterozygous and homozygous Parn KO mice","pmids":["30770239","31387300","31273937"],"confidence":"Medium","gaps":["Some mechanistic links inferred from expression data","Identity of the S557 kinase under DNA damage not defined here"]},{"year":2020,"claim":"Revealed compartmentalized PARN function, showing ER-anchored PARN shapes ER-associated transcript poly(A) profiles and that MK2 phosphorylation of Ser557 drives its DNA-damage relocalization from ER to cytosol.","evidence":"Subcellular fractionation, liposome insertion of purified PARN, ER-anchored constructs, ER-RNA transcriptomics, and MK2 phosphorylation assay","pmids":["31936572"],"confidence":"Medium","gaps":["Single-lab study; mechanism of ER anchoring partly inferred","Generality of ER pool beyond tested transcripts unknown"]},{"year":2023,"claim":"Demonstrated a disease-relevant feedforward circuit, with PARN sustaining EGFR by degrading miR-7 to drive STAT3-dependent PARN expression and tumor infiltration in glioblastoma stem cells.","evidence":"PARN knockdown, miR-7/EGFR/STAT3 assays, and orthotopic xenograft survival with STAT3 inhibition","pmids":["37747775"],"confidence":"Medium","gaps":["Directness of PARN action on miR-7 vs indirect effects not fully separated","Single tumor model"]},{"year":2024,"claim":"Extended PARN to metabolic physiology, showing it partners with PTBP1 to regulate Slc30a8/Chst3 mRNA stability and is required for glucose-stimulated insulin secretion.","evidence":"β-cell conditional Parn KO mice, PARN-PTBP1 co-IP, LACE-seq, and GSIS assays","pmids":["39297407"],"confidence":"Medium","gaps":["Whether deadenylation per se underlies the secretion phenotype not fully isolated","Single lab"]},{"year":2026,"claim":"Showed PARN acts on poly(A) site choice and miRNA biogenesis in vivo, promoting proximal poly(A) usage and Foxp1 destabilization in B cells, and forming a mutual feedback loop with miR-29a/miR-1207 via CPSF6 recruitment.","evidence":"Conditional B-cell Parn KO with genome-wide poly(A) sequencing and antibody assays; PARN/CPSF6 co-IP, pri-miRNA RIP, and PARN 3'-UTR reporters with migration assays","pmids":["42118147","41825960"],"confidence":"Medium","gaps":["Mechanism coupling deadenylation to poly(A) site selection unresolved","Single-lab findings awaiting independent replication"]},{"year":null,"claim":"How the many cofactor-recruitment and phosphorylation inputs are integrated to direct PARN between its mRNA-decay, ncRNA-maturation, and compartment-specific functions in a given cell state remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model integrating cofactor selection with localization switching","Quantitative substrate hierarchy in vivo not established","Kinase network controlling PARN phosphosites incompletely mapped"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140098","term_label":"catalytic activity, acting on RNA","supporting_discovery_ids":[0,1,3,7,8,19]},{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[0,1,24]},{"term_id":"GO:0003723","term_label":"RNA binding","supporting_discovery_ids":[0,1,14,16,27,28]}],"localization":[{"term_id":"GO:0005730","term_label":"nucleolus","supporting_discovery_ids":[3,15]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[1,15]},{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[21]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[21]}],"pathway":[{"term_id":"R-HSA-8953854","term_label":"Metabolism of RNA","supporting_discovery_ids":[3,4,7,8,10]},{"term_id":"R-HSA-1852241","term_label":"Organelle biogenesis and maintenance","supporting_discovery_ids":[12,20]}],"complexes":[],"partners":["PAPD5","CUGBP1","NCL","AGO2","PTBP1","CPSF6","CBP80","DKC1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"O95453","full_name":"Poly(A)-specific ribonuclease PARN","aliases":["Deadenylating nuclease","Deadenylation nuclease","Polyadenylate-specific ribonuclease"],"length_aa":639,"mass_kda":73.5,"function":"3'-exoribonuclease that has a preference for poly(A) tails of mRNAs, thereby efficiently degrading poly(A) tails. Exonucleolytic degradation of the poly(A) tail is often the first step in the decay of eukaryotic mRNAs and is also used to silence certain maternal mRNAs translationally during oocyte maturation and early embryonic development. Interacts with both the 3'-end poly(A) tail and the 5'-end cap structure during degradation, the interaction with the cap structure being required for an efficient degradation of poly(A) tails. Involved in nonsense-mediated mRNA decay, a critical process of selective degradation of mRNAs that contain premature stop codons. Also involved in degradation of inherently unstable mRNAs that contain AU-rich elements (AREs) in their 3'-UTR, possibly via its interaction with KHSRP. Probably mediates the removal of poly(A) tails of AREs mRNAs, which constitutes the first step of destabilization (PubMed:10882133, PubMed:11359775, PubMed:12748283, PubMed:15175153, PubMed:9736620). Also able to recognize and trim poly(A) tails of microRNAs such as MIR21 and H/ACA box snoRNAs (small nucleolar RNAs) leading to microRNAs degradation or snoRNA increased stability (PubMed:22442037, PubMed:25049417)","subcellular_location":"Nucleus; Cytoplasm; Nucleus, nucleolus","url":"https://www.uniprot.org/uniprotkb/O95453/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/PARN","classification":"Not Classified","n_dependent_lines":385,"n_total_lines":1208,"dependency_fraction":0.31870860927152317},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"BYSL","stoichiometry":10.0},{"gene":"DHX37","stoichiometry":4.0},{"gene":"UTP14A","stoichiometry":4.0},{"gene":"TSR1","stoichiometry":0.2},{"gene":"FAM207A","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/PARN","total_profiled":1310},"omim":[{"mim_id":"619529","title":"PARN-LIKE RIBONUCLEASE DOMAIN-CONTAINING EXONUCLEASE 1; PNLDC1","url":"https://www.omim.org/entry/619529"},{"mim_id":"619528","title":"SPERMATOGENIC FAILURE 57; SPGF57","url":"https://www.omim.org/entry/619528"},{"mim_id":"616373","title":"PULMONARY FIBROSIS AND/OR BONE MARROW FAILURE SYNDROME, TELOMERE-RELATED, 3; PFBMFT3","url":"https://www.omim.org/entry/616373"},{"mim_id":"616371","title":"PULMONARY FIBROSIS AND/OR BONE MARROW FAILURE SYNDROME, TELOMERE-RELATED, 4; PFBMFT4","url":"https://www.omim.org/entry/616371"},{"mim_id":"616353","title":"DYSKERATOSIS CONGENITA, AUTOSOMAL RECESSIVE 6; DKCB6","url":"https://www.omim.org/entry/616353"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nuclear speckles","reliability":"Supported"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/PARN"},"hgnc":{"alias_symbol":["DAN"],"prev_symbol":[]},"alphafold":{"accession":"O95453","domains":[{"cath_id":"3.30.420.10","chopping":"3-134_270-432","consensus_level":"high","plddt":94.7179,"start":3,"end":432},{"cath_id":"3.30.1370.50","chopping":"159-243","consensus_level":"high","plddt":83.5602,"start":159,"end":243},{"cath_id":"3.30.70.330","chopping":"448-516","consensus_level":"high","plddt":91.7997,"start":448,"end":516}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O95453","model_url":"https://alphafold.ebi.ac.uk/files/AF-O95453-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O95453-F1-predicted_aligned_error_v6.png","plddt_mean":81.06},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=PARN","jax_strain_url":"https://www.jax.org/strain/search?query=PARN"},"sequence":{"accession":"O95453","fasta_url":"https://rest.uniprot.org/uniprotkb/O95453.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O95453/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O95453"}},"corpus_meta":[{"pmid":"25848748","id":"PMC_25848748","title":"Exome sequencing links mutations in PARN and RTEL1 with familial pulmonary fibrosis and telomere shortening.","date":"2015","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25848748","citation_count":383,"is_preprint":false},{"pmid":"26482878","id":"PMC_26482878","title":"Poly(A)-specific ribonuclease (PARN) mediates 3'-end maturation of the telomerase RNA component.","date":"2015","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/26482878","citation_count":156,"is_preprint":false},{"pmid":"16601207","id":"PMC_16601207","title":"CUG-BP binds to RNA substrates and recruits PARN deadenylase.","date":"2006","source":"RNA (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/16601207","citation_count":153,"is_preprint":false},{"pmid":"22442037","id":"PMC_22442037","title":"Maturation of mammalian H/ACA box snoRNAs: PAPD5-dependent adenylation and PARN-dependent trimming.","date":"2012","source":"RNA (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/22442037","citation_count":134,"is_preprint":false},{"pmid":"26919432","id":"PMC_26919432","title":"The RNase PARN-1 Trims piRNA 3' Ends to Promote Transcriptome Surveillance in C. elegans.","date":"2016","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26919432","citation_count":118,"is_preprint":false},{"pmid":"26950371","id":"PMC_26950371","title":"Inhibition of telomerase RNA decay rescues telomerase deficiency caused by dyskerin or PARN defects.","date":"2016","source":"Nature structural & molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/26950371","citation_count":103,"is_preprint":false},{"pmid":"16281054","id":"PMC_16281054","title":"Structural insight into poly(A) binding and catalytic mechanism of human PARN.","date":"2005","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/16281054","citation_count":99,"is_preprint":false},{"pmid":"11424938","id":"PMC_11424938","title":"The mechanism and regulation of deadenylation: identification and characterization of Xenopus PARN.","date":"2001","source":"RNA (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/11424938","citation_count":88,"is_preprint":false},{"pmid":"26342108","id":"PMC_26342108","title":"Bone marrow failure and developmental delay caused by mutations in poly(A)-specific ribonuclease (PARN).","date":"2015","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/26342108","citation_count":85,"is_preprint":false},{"pmid":"15247430","id":"PMC_15247430","title":"mRNA deadenylation by PARN is essential for embryogenesis in higher plants.","date":"2004","source":"RNA (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/15247430","citation_count":74,"is_preprint":false},{"pmid":"29669292","id":"PMC_29669292","title":"PARN and TOE1 Constitute a 3' End Maturation Module for Nuclear Non-coding RNAs.","date":"2018","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/29669292","citation_count":69,"is_preprint":false},{"pmid":"26130707","id":"PMC_26130707","title":"Destabilization of microRNAs in human cells by 3' deadenylation mediated by PARN and CUGBP1.","date":"2015","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/26130707","citation_count":65,"is_preprint":false},{"pmid":"30770239","id":"PMC_30770239","title":"The RNase PARN Controls the Levels of Specific miRNAs that Contribute to p53 Regulation.","date":"2019","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/30770239","citation_count":63,"is_preprint":false},{"pmid":"23496118","id":"PMC_23496118","title":"Poly(A)-specific ribonuclease (PARN): an allosterically regulated, processive and mRNA cap-interacting deadenylase.","date":"2013","source":"Critical reviews in biochemistry and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/23496118","citation_count":60,"is_preprint":false},{"pmid":"22956911","id":"PMC_22956911","title":"The PARN deadenylase targets a discrete set of mRNAs for decay and regulates cell motility in mouse myoblasts.","date":"2012","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22956911","citation_count":48,"is_preprint":false},{"pmid":"26400160","id":"PMC_26400160","title":"PARN deadenylase is involved in miRNA-dependent degradation of TP53 mRNA in mammalian cells.","date":"2015","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/26400160","citation_count":43,"is_preprint":false},{"pmid":"30575725","id":"PMC_30575725","title":"The H/ACA complex disrupts triplex in hTR precursor to permit processing by RRP6 and PARN.","date":"2018","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/30575725","citation_count":42,"is_preprint":false},{"pmid":"15653638","id":"PMC_15653638","title":"Serum-deprivation stimulates cap-binding by PARN at the expense of eIF4E, consistent with the observed decrease in mRNA stability.","date":"2005","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/15653638","citation_count":42,"is_preprint":false},{"pmid":"31273937","id":"PMC_31273937","title":"Impaired telomere integrity and rRNA biogenesis in PARN-deficient patients and knock-out models.","date":"2019","source":"EMBO molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31273937","citation_count":41,"is_preprint":false},{"pmid":"23274303","id":"PMC_23274303","title":"Kiss your tail goodbye: the role of PARN, Nocturnin, and Angel deadenylases in mRNA biology.","date":"2012","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/23274303","citation_count":38,"is_preprint":false},{"pmid":"26810774","id":"PMC_26810774","title":"Hoyeraal-Hreidarsson Syndrome due to PARN Mutations: Fourteen Years of Follow-Up.","date":"2015","source":"Pediatric neurology","url":"https://pubmed.ncbi.nlm.nih.gov/26810774","citation_count":35,"is_preprint":false},{"pmid":"28760775","id":"PMC_28760775","title":"PARN Modulates Y RNA Stability and Its 3'-End Formation.","date":"2017","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/28760775","citation_count":32,"is_preprint":false},{"pmid":"25499764","id":"PMC_25499764","title":"Depletion of poly(A)-specific ribonuclease (PARN) inhibits proliferation of human gastric cancer cells by blocking cell cycle progression.","date":"2014","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/25499764","citation_count":30,"is_preprint":false},{"pmid":"22834816","id":"PMC_22834816","title":"Modulation of poly(A)-specific ribonuclease (PARN): current knowledge and perspectives.","date":"2012","source":"Current medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22834816","citation_count":29,"is_preprint":false},{"pmid":"29168431","id":"PMC_29168431","title":"Nucleolin phosphorylation regulates PARN deadenylase activity during cellular stress response.","date":"2017","source":"RNA biology","url":"https://pubmed.ncbi.nlm.nih.gov/29168431","citation_count":29,"is_preprint":false},{"pmid":"19472977","id":"PMC_19472977","title":"Competitive inhibition of human poly(A)-specific ribonuclease (PARN) by synthetic fluoro-pyranosyl nucleosides.","date":"2009","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19472977","citation_count":28,"is_preprint":false},{"pmid":"31448843","id":"PMC_31448843","title":"From incomplete penetrance with normal telomere length to severe disease and telomere shortening in a family with monoallelic and biallelic PARN pathogenic variants.","date":"2019","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/31448843","citation_count":24,"is_preprint":false},{"pmid":"37747775","id":"PMC_37747775","title":"Cross-talk between PARN and EGFR-STAT3 Signaling Facilitates Self-Renewal and Proliferation of Glioblastoma Stem Cells.","date":"2023","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/37747775","citation_count":22,"is_preprint":false},{"pmid":"21743004","id":"PMC_21743004","title":"PolyA-specific ribonuclease (PARN-1) function in stage-specific mRNA turnover in Trypanosoma brucei.","date":"2011","source":"Eukaryotic cell","url":"https://pubmed.ncbi.nlm.nih.gov/21743004","citation_count":18,"is_preprint":false},{"pmid":"22041582","id":"PMC_22041582","title":"Kinetic and in silico analysis of the slow-binding inhibition of human poly(A)-specific ribonuclease (PARN) by novel nucleoside analogues.","date":"2011","source":"Biochimie","url":"https://pubmed.ncbi.nlm.nih.gov/22041582","citation_count":16,"is_preprint":false},{"pmid":"10640832","id":"PMC_10640832","title":"The human gene for the poly(A)-specific ribonuclease (PARN) maps to 16p13 and has a truncated copy in the Prader-Willi/Angelman syndrome region on 15q11-->q13.","date":"1999","source":"Cytogenetics and cell genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10640832","citation_count":15,"is_preprint":false},{"pmid":"37544646","id":"PMC_37544646","title":"The PARN, TOE1, and USB1 RNA deadenylases and their roles in non-coding RNA regulation.","date":"2023","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/37544646","citation_count":14,"is_preprint":false},{"pmid":"16620953","id":"PMC_16620953","title":"Expression and purification of recombinant poly(A)-specific ribonuclease (PARN).","date":"2006","source":"International journal of biological macromolecules","url":"https://pubmed.ncbi.nlm.nih.gov/16620953","citation_count":14,"is_preprint":false},{"pmid":"34520768","id":"PMC_34520768","title":"Poly (A)-specific ribonuclease (PARN): More than just \"mRNA stock clearing\".","date":"2021","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34520768","citation_count":13,"is_preprint":false},{"pmid":"33244623","id":"PMC_33244623","title":"Multiple bilateral hip fractures in a patient with dyskeratosis congenita caused by a novel mutation in the PARN gene.","date":"2020","source":"Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA","url":"https://pubmed.ncbi.nlm.nih.gov/33244623","citation_count":13,"is_preprint":false},{"pmid":"25239613","id":"PMC_25239613","title":"Self-association of poly(A)-specific ribonuclease (PARN) triggered by the R3H domain.","date":"2014","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/25239613","citation_count":12,"is_preprint":false},{"pmid":"18763168","id":"PMC_18763168","title":"Inhibition of human poly(A)-specific ribonuclease (PARN) by purine nucleotides: kinetic analysis.","date":"2009","source":"Journal of enzyme inhibition and medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18763168","citation_count":12,"is_preprint":false},{"pmid":"32452087","id":"PMC_32452087","title":"CD8+ T-cell senescence and skewed lymphocyte subsets in young Dyskeratosis Congenita patients with PARN and DKC1 mutations.","date":"2020","source":"Journal of clinical laboratory analysis","url":"https://pubmed.ncbi.nlm.nih.gov/32452087","citation_count":11,"is_preprint":false},{"pmid":"31387300","id":"PMC_31387300","title":"The Intrinsically Disordered C-Terminal Domain Triggers Nucleolar Localization and Function Switch of PARN in Response to DNA Damage.","date":"2019","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/31387300","citation_count":9,"is_preprint":false},{"pmid":"28011629","id":"PMC_28011629","title":"A feedback mechanism between PLD and deadenylase PARN for the shortening of eukaryotic poly(A) mRNA tails that is deregulated in cancer cells.","date":"2017","source":"Biology open","url":"https://pubmed.ncbi.nlm.nih.gov/28011629","citation_count":8,"is_preprint":false},{"pmid":"31936572","id":"PMC_31936572","title":"Translation Efficiency and Degradation of ER-Associated mRNAs Modulated by ER-Anchored poly(A)-Specific Ribonuclease (PARN).","date":"2020","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/31936572","citation_count":7,"is_preprint":false},{"pmid":"39297407","id":"PMC_39297407","title":"PARN Maintains RNA Stability to Regulate Insulin Maturation and GSIS in Pancreatic β Cells.","date":"2024","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/39297407","citation_count":4,"is_preprint":false},{"pmid":"30949591","id":"PMC_30949591","title":"Contributions of the C-terminal domain to poly(A)-specific ribonuclease (PARN) stability and self-association.","date":"2019","source":"Biochemistry and biophysics reports","url":"https://pubmed.ncbi.nlm.nih.gov/30949591","citation_count":4,"is_preprint":false},{"pmid":"26772900","id":"PMC_26772900","title":"Molecular recognition of mRNA 5' cap by 3' poly(A)-specific ribonuclease (PARN) differs from interactions known for other cap-binding proteins.","date":"2016","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/26772900","citation_count":4,"is_preprint":false},{"pmid":"39649862","id":"PMC_39649862","title":"Hoyeraal-Hreidarsson syndrome: a case report of dyskeratosis congenita with a novel PARN gene mutation.","date":"2024","source":"Annals of medicine and surgery (2012)","url":"https://pubmed.ncbi.nlm.nih.gov/39649862","citation_count":3,"is_preprint":false},{"pmid":"29055513","id":"PMC_29055513","title":"[A rare familial form of idiopathic pulmonary fibrosis with Poly(A)-specific ribonuclease (PARN) mutation].","date":"2017","source":"Revue de pneumologie clinique","url":"https://pubmed.ncbi.nlm.nih.gov/29055513","citation_count":3,"is_preprint":false},{"pmid":"35092390","id":"PMC_35092390","title":"PARN Knockdown in Cell Lines Results in Differential and Cell-Specific Alterations in the Expression of Cancer-Associated mRNAs.","date":"2022","source":"Asian Pacific journal of cancer prevention : APJCP","url":"https://pubmed.ncbi.nlm.nih.gov/35092390","citation_count":2,"is_preprint":false},{"pmid":"40896794","id":"PMC_40896794","title":"Optical Genomic Mapping and Next-Generation Sequencing Identified Retrotransposon Insertion and Missense Variant Disrupting PARN Gene in Dyskeratosis Congenita.","date":"2025","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/40896794","citation_count":2,"is_preprint":false},{"pmid":"40859110","id":"PMC_40859110","title":"RNA Analysis Uncovers Pathogenic PARN Variant in Dyskeratosis Congenita.","date":"2025","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/40859110","citation_count":2,"is_preprint":false},{"pmid":"38766974","id":"PMC_38766974","title":"Chemical composition and biological activities of essential oil of the Malaysian endemic Syzygium variolosum (King) Chantar. & J.Parn.","date":"2024","source":"Natural product research","url":"https://pubmed.ncbi.nlm.nih.gov/38766974","citation_count":2,"is_preprint":false},{"pmid":"40438983","id":"PMC_40438983","title":"Germline PARN Variants in Telomere Biology Disorders and Challenges in Variant Curation.","date":"2025","source":"Molecular genetics & genomic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/40438983","citation_count":1,"is_preprint":false},{"pmid":"37002320","id":"PMC_37002320","title":"Identification of PARN nuclease activity inhibitors by computational-based docking and high-throughput screening.","date":"2023","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/37002320","citation_count":1,"is_preprint":false},{"pmid":"41530371","id":"PMC_41530371","title":"MAT2A enhances PARN transcription via SRF to accelerate glycolysis and drive malignant progression in osteosarcoma.","date":"2026","source":"Communications biology","url":"https://pubmed.ncbi.nlm.nih.gov/41530371","citation_count":0,"is_preprint":false},{"pmid":"41741124","id":"PMC_41741124","title":"Monoallelic PARN mutation presenting as pancytopenia, hepatic fibrosis and idiopathic pulmonary fibrosis.","date":"2026","source":"BMJ case reports","url":"https://pubmed.ncbi.nlm.nih.gov/41741124","citation_count":0,"is_preprint":false},{"pmid":"41825960","id":"PMC_41825960","title":"Mutual feedback regulation between Poly(A)-specific ribonuclease (PARN) and cognate microRNAs.","date":"2026","source":"Life science alliance","url":"https://pubmed.ncbi.nlm.nih.gov/41825960","citation_count":0,"is_preprint":false},{"pmid":"42118147","id":"PMC_42118147","title":"The RNA-Binding Protein PARN Remodeled 3' UTR Structure Defines Poly(A)-Loading Sites to Mediate Immunoglobulin Homeostasis.","date":"2026","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/42118147","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":26238,"output_tokens":7977,"usd":0.099184,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":17367,"output_tokens":4866,"usd":0.104243,"stage2_stop_reason":"end_turn"},"total_usd":0.203427,"stage1_batch_id":"msgbatch_013a8chtv3AWyTqv4z4sEF4C","stage2_batch_id":"msgbatch_01AHsuW63vinsvuTgzmQ3n62","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2005,\n      \"finding\": \"Crystal structure of C-terminal truncated human PARN in free and RNA-bound forms reveals a homodimer with an R3H domain and a nuclease domain; the R3H domain of one subunit partially encloses the active site of the other, poly(A) binds in a deep cavity in a sequence-nonspecific manner, and mutations disrupting dimerization abolish both enzymatic and RNA-binding activities, establishing the dimer as the structural and functional unit. The cap-binding domain acts with the R3H domain to amplify processivity.\",\n      \"method\": \"X-ray crystallography (free and RNA-bound forms) combined with dimerization-disrupting mutagenesis and enzymatic activity assays\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure with functional mutagenesis validating dimerization requirement for catalysis\",\n      \"pmids\": [\"16281054\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Xenopus PARN (xPARN) is a poly(A)-specific 3' exonuclease that copurifies as 62 kDa and 74 kDa polypeptides (the 62 kDa being a proteolytic product). It contains a tripartite exonuclease domain, a putative RNA recognition motif, and an MCM-like domain. It can be activated in the oocyte nucleus independently of cytoplasmic components, and nuclear export of deadenylated RNA is impeded. The enzyme binds poly(A) in the absence of catalysis, contributing to substrate specificity.\",\n      \"method\": \"Protein purification, molecular cloning, in vitro deadenylation assay, microinjection into Xenopus oocytes, western blot\",\n      \"journal\": \"RNA (New York, N.Y.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — biochemical reconstitution with in vitro assay plus in vivo microinjection; single lab but multiple orthogonal methods\",\n      \"pmids\": [\"11424938\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"CUG-BP (CUGBP1) binds ARE-containing mRNAs (c-fos, TNFα) and directly recruits PARN deadenylase to stimulate poly(A) shortening. CUG-BP interacts with PARN in cell extracts by co-immunoprecipitation, and this interaction is recapitulated with recombinant proteins, identifying CUG-BP as the first RNA-binding protein shown to directly recruit a deadenylase to an RNA substrate.\",\n      \"method\": \"In vitro deadenylation assay, co-immunoprecipitation from extracts, recombinant protein pulldown\",\n      \"journal\": \"RNA (New York, N.Y.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — in vitro reconstitution of recruitment plus reciprocal co-IP with recombinant proteins, single lab\",\n      \"pmids\": [\"16601207\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"PARN knockdown in human cells causes accumulation of oligoadenylated processing intermediates of H/ACA box snoRNAs and scaRNAs (but not C/D box RNAs). PARN is concentrated in nucleoli and Cajal bodies. The non-canonical poly(A) polymerase PAPD5 adds oligo(A) tails to snoRNA 3' stubs, and PARN removes these tails to complete 3' end maturation, coupling deadenylation to clean trimming and snoRNA stabilization.\",\n      \"method\": \"siRNA knockdown, deep sequencing of RNA 3' ends, immunofluorescence localization, PAPD5 knockdown epistasis\",\n      \"journal\": \"RNA (New York, N.Y.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis (PARN + PAPD5 knockdown), 3'-end sequencing, and localization in single study with multiple orthogonal methods\",\n      \"pmids\": [\"22442037\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"PARN is required for 3'-end maturation of the telomerase RNA component (TERC). Patient-derived cells with PARN mutations show decreased TERC levels and increased oligo(A)-tailed forms of TERC. Deep sequencing demonstrates that PARN removes post-transcriptionally acquired oligo(A) tails that target TERC for nuclear degradation. Restoring PARN normalizes TERC levels and the proportion of oligo(A) forms.\",\n      \"method\": \"Deep sequencing of TERC 3' ends in patient-derived somatic cells and iPSCs, PARN complementation rescue, PARN disruption in immortalized cells\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — replicated across patient-derived and engineered cell models with deep sequencing and rescue experiments\",\n      \"pmids\": [\"26482878\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"PARN increases human telomerase RNA (hTR) levels by deadenylating hTR, thereby limiting its degradation by EXOSC10 (which is recruited following PAPD5-mediated oligoadenylation). Defects in dyskerin binding lead to hTR degradation via PAPD5 oligoadenylation → EXOSC10 3'-to-5' decay, as well as decapping by DCP2 and 5'-to-3' decay by XRN1. Knockdown of DCP2 and/or EXOSC10 rescues telomerase activity and hTR localization in PARN-deficient cells.\",\n      \"method\": \"Knockdown epistasis (PARN, PAPD5, EXOSC10, DCP2, XRN1), hTR level and localization measurements, telomerase activity assays\",\n      \"journal\": \"Nature structural & molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multi-component epistasis with multiple knockdowns and rescue, replicated across dyskerin- and PARN-deficient contexts\",\n      \"pmids\": [\"26950371\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"PARN deadenylase activity is required for deadenylation of miR-122 in human cells; PARN knockdown leads to accumulation of 3'-oligoadenylated miR-122 and increased miR-122 stability. CUGBP1 specifically interacts with miR-122 and other UG-rich miRNAs, interacts directly with PARN, and recruits PARN to miR-122 to enhance PARN-mediated deadenylation and degradation in a dose-dependent manner in vitro.\",\n      \"method\": \"PARN knockdown, deep sequencing of miRNA 3' ends, in vitro deadenylation assay with CUGBP1, PARN/CUGBP1 co-immunoprecipitation\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — in vitro reconstitution of CUGBP1-stimulated PARN activity on miRNA plus cell-based knockdown with 3'-end sequencing\",\n      \"pmids\": [\"26130707\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"PARN regulates the levels of numerous miRNAs by removing oligo(A) tails added by PAPD5; remaining oligo(A) tails recruit the exonucleases DIS3L or DIS3L2 to degrade the miRNA. PARN knockdown destabilizes multiple miRNAs that repress p53 translation, leading to p53 accumulation in a Dicer-dependent manner, explaining the p53 elevation in PARN-defective patients.\",\n      \"method\": \"PARN/PAPD5/DIS3L/DIS3L2 knockdown epistasis, miRNA 3'-end sequencing, p53 protein measurement, Dicer-dependence experiment\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multi-component epistasis with multiple knockdowns and rescue across orthogonal methods in a single rigorous study\",\n      \"pmids\": [\"30770239\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"PARN depletion reduces levels of abundant human Y RNAs. PAPD5 depletion or DIS3L knockdown rescues the effect of PARN depletion on Y RNA levels, establishing that PARN stabilizes Y RNAs by removing PAPD5-added oligoadenylated tails that otherwise recruit DIS3L for degradation. PARN also deadenylates U6 and RMRP RNAs without affecting their levels.\",\n      \"method\": \"PARN/PAPD5/DIS3L knockdown epistasis, deep sequencing of RNA 3' ends\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis with multiple knockdowns confirmed by 3'-end sequencing, single lab\",\n      \"pmids\": [\"28760775\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"PARN and TOE1 act redundantly on small Cajal body-specific RNAs (scaRNAs) and on TERC biogenesis. Combined depletion of PARN and TOE1 strongly downregulates scaRNAs, leading to defects in snRNA pseudouridylation. Neither enzyme alone targets mRNA poly(A) tails; their substrates are nuclear small ncRNAs.\",\n      \"method\": \"mTAIL-seq, RNA-seq, double knockdown of PARN and TOE1, snRNA pseudouridylation assay\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — double-knockdown epistasis combined with genome-wide 3'-end sequencing and functional snRNA pseudouridylation readout\",\n      \"pmids\": [\"29669292\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"TERC precursor processing by PARN and RRP6 occurs in two steps: longer 3'-extended precursors are first trimmed by RRP6, then shorter forms are processed by PARN. H/ACA RNP assembly actively promotes productive processing and protects the mature 3' end; tertiary RNA interactions in longer transcripts favor degradation over processing.\",\n      \"method\": \"In vitro RNA processing assays with purified PARN and RRP6, H/ACA RNP assembly assays, RNA structure probing\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with purified enzymes, RNP assembly assays, and structural analysis, single lab\",\n      \"pmids\": [\"30575725\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"In C. elegans, PARN-1 (the PARN ortholog) trims piRNA 3' ends; PARN-1-deficient animals accumulate untrimmed piRNAs with 3' extensions. Longer piRNAs associate with the Piwi protein PRG-1 but fail to robustly recruit downstream silencing factors, demonstrating that precise piRNA length determined by PARN-1 is required for efficient transcriptome surveillance.\",\n      \"method\": \"PARN-1 loss-of-function genetics in C. elegans, deep sequencing of piRNAs, PRG-1 co-immunoprecipitation, silencing factor recruitment assay\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic loss-of-function in model organism with deep sequencing and biochemical validation of PRG-1 binding vs. silencing factor recruitment\",\n      \"pmids\": [\"26919432\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Cells from patients with biallelic PARN mutations have severely reduced PARN deadenylation activity and impaired oligoadenylation of specific H/ACA box snoRNAs. PARN-deficient patient cells display short telomeres and aberrant ribosome profiles. Knockdown of PARN in human marrow cells and zebrafish impairs haematopoiesis.\",\n      \"method\": \"Biochemical deadenylation activity assay on patient cells, snoRNA oligoadenylation analysis, telomere length measurement, ribosome profile, PARN knockdown in human marrow cells and zebrafish morpholino experiments\",\n      \"journal\": \"Journal of medical genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (biochemical, cell biology, in vivo model) in single study; patient cell findings replicated in zebrafish model\",\n      \"pmids\": [\"26342108\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"PARN knockdown in mouse myoblasts stabilizes a defined set of ~40 mRNAs including ZFP36L2, and increases Zfp36l2 poly(A) tail length and translation. The PARN-dependent regulatory elements reside in the 3' UTR. PARN knockdown also broadly affects gene expression, reducing levels of mRNAs encoding cell migration and adhesion factors; PARN-depleted cells migrate faster in wound-healing assays.\",\n      \"method\": \"Stable PARN knockdown, global mRNA half-life analysis, poly(A) tail length assay, 3' UTR reporter assay, wound-healing migration assay\",\n      \"journal\": \"PLoS genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genome-wide mRNA stability analysis plus mechanistic 3' UTR reporter and functional migration assay, single lab\",\n      \"pmids\": [\"22956911\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Molecular recognition of the mRNA 5' cap by PARN differs from other cap-binding proteins: PARN dimer subunits show negative cooperativity in cap binding; non-coulombic interactions dominate complex formation; and PARN has versatile activity toward alternative cap forms. Cap binding amplifies the processivity of PARN deadenylation.\",\n      \"method\": \"Surface plasmon resonance kinetics, quantitative equilibrium fluorescence titrations, circular dichroism\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — multiple biophysical methods (SPR, fluorescence titration, CD) in single lab establishing cap-binding mechanism\",\n      \"pmids\": [\"26772900\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"The intrinsically disordered C-terminal domain (CTD) of PARN contains nuclear and nucleolar localization signals. Phosphorylation-mimic mutation S557D disrupts local CTD structure and alters binding partner selection: under normal conditions nucleolus-residing PARN recruits CBP80 to repress deadenylase activity; DNA damage-induced phosphorylation of S557 expels CBP80 from nucleoli (releasing activity inhibition) and recruits CstF-50 into nucleoli to activate deadenylation. This function switch reshapes the profile of small nuclear ncRNAs in response to DNA damage.\",\n      \"method\": \"Mutagenesis (S557D phospho-mimic), spectroscopic analysis of CTD structure, fluorescence microscopy of protein localization, co-immunoprecipitation of CBP80 and CstF-50, ncRNA profiling\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — phospho-mimic mutagenesis combined with localization imaging and co-IP identifying distinct partners, single lab\",\n      \"pmids\": [\"31387300\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"PARN is a phosphoprotein and its phosphorylation state is modulated by serum status. Under serum deprivation, cap association by PARN increases while eIF4E cap occupancy decreases, suggesting a competition at the 5' cap regulated by post-translational phosphorylation of PARN that influences whether mRNA is translated or decayed.\",\n      \"method\": \"Cap-binding fractionation assay, phosphoprotein analysis, serum starvation treatment, reporter translation assay\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct cap-binding and phosphorylation measurements under defined conditions, single lab, multiple methods\",\n      \"pmids\": [\"15653638\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"PARN mediates miRNA-dependent degradation of TP53 mRNA. Argonaute-2 (Ago-2), the core component of miRISC, co-exists in complexes with PARN and activates its deadenylase activity. miR-125b-loaded miRISC recruits PARN to TP53 mRNA via both an ARE and an adjacent miR-125b/miR-504 targeting site in the 3' UTR; HuR can revert this recruitment.\",\n      \"method\": \"Co-immunoprecipitation of Ago-2 with PARN, in vitro deadenylase activity assay, 3' UTR reporter assays, PARN knockdown mRNA stability measurement\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP of PARN-Ago2 complex plus in vitro activity and 3' UTR reporter, single lab\",\n      \"pmids\": [\"26400160\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Nucleolin (NCL) phosphorylation at CK2 consensus sites is required to activate PARN deadenylase activity upon oncogenic stimuli and UV stress. NCL interacts directly with PARN and, under non-stress conditions, forms complexes with p53 and HuR. Phosphorylation-deficient NCL (NCL-6/S*A) cannot activate PARN, and hypophosphorylated NCL favors interactions with HuR and p53. NCL interacts with PARN substrate mRNAs including TP53 and BCL2.\",\n      \"method\": \"Co-immunoprecipitation of NCL with PARN, deadenylase activity assay with WT vs. phospho-deficient NCL, UV stress treatment, mRNA stability measurement\",\n      \"journal\": \"RNA biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct binding assay plus functional deadenylase activity with phospho-mutant, single lab\",\n      \"pmids\": [\"29168431\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"PARN can self-associate into tetramers and higher-order oligomers both in vitro and in living cells. Self-association is triggered by the R3H domain, which causes burial of Trp219 in a solvent-inaccessible environment. The RRM and C-terminal domains modulate the dissociation rate of tetrameric PARN. Tetramerization significantly enhances the catalytic activity and processivity of the truncated form lacking the RRM and C-terminal domains.\",\n      \"method\": \"Analytical ultracentrifugation/size-exclusion chromatography for oligomerization, site-directed mutagenesis of R3H domain, tryptophan fluorescence spectroscopy, in vitro deadenylase activity assay of truncations\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro biochemical reconstitution with mutagenesis and enzymatic assay, single lab\",\n      \"pmids\": [\"25239613\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"PARN deficiency compromises ribosomal RNA biogenesis in patient fibroblasts and heterozygous Parn knockout mice. PARN deficiency down-regulates shelterin transcripts (TRF1, TRF2, TPP1, RAP1, POT1) and DKC1 mRNA (the latter through p53 activation). Homozygous Parn KO causes early embryonic lethality not rescued by p53 KO.\",\n      \"method\": \"Patient fibroblast analysis, inducible PARN KO and complementation cell line, heterozygous Parn KO mice, rRNA biogenesis assay, RT-qPCR for shelterin transcripts, double Parn/p53 KO\",\n      \"journal\": \"EMBO molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple model systems (patient cells, KO mouse, inducible KO cell line), single lab, but mechanisms partially inferred from expression data\",\n      \"pmids\": [\"31273937\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"PARN is anchored to the endoplasmic reticulum (ER) surface where it reshapes the poly(A) length profile of ER-associated RNAs by suppressing long poly(A) tails. ER-anchored PARN triggers degradation of a subset of ER-enriched transcripts including MDM2, modulating DNA damage response and cell viability. MK2 kinase phosphorylates PARN-Ser557 during DNA damage to promote PARN translocation from the ER to the cytosol.\",\n      \"method\": \"Subcellular fractionation, liposome insertion assay with purified PARN, ER-anchored PARN expression constructs, transcriptome sequencing of ER-associated RNAs, MK2 kinase phosphorylation assay, poly(A) tail length analysis\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — biochemical reconstitution of membrane insertion plus cell-based fractionation and functional transcriptomics, single lab\",\n      \"pmids\": [\"31936572\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Synthetic fluoro-pyranosyl nucleoside analogues (cytosine- and adenine-based) competitively inhibit human PARN at its active site. Kinetic analysis shows the inhibition is competitive and cannot be released by altering Mg²⁺ concentration. Molecular docking indicates the sugar moiety stabilizes the compounds in the active site through interactions with catalytic residues.\",\n      \"method\": \"In vitro PARN deadenylase activity kinetic analysis, molecular docking and molecular dynamics simulation\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinetic analysis with defined mechanism plus computational docking, single lab\",\n      \"pmids\": [\"19472977\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Novel uracil-based glucopyranosyl nucleoside analogues (including U1) inhibit human PARN via slow-binding, slow-release competitive inhibition at the active site, with Ki values in the low µM range (11–33-fold lower than previously reported adenosine/cytosine analogues). Molecular docking confirms binding at the PARN active site.\",\n      \"method\": \"In vitro kinetic analysis (slow-binding inhibition kinetics), molecular docking\",\n      \"journal\": \"Biochimie\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — detailed kinetic mechanism with slow-binding analysis plus docking, single lab\",\n      \"pmids\": [\"22041582\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Purine nucleotides inhibit human PARN in vitro: RTP nucleotides act as non-competitive inhibitors, while RDP and RMP exhibit competitive inhibition. Mg²⁺ can release inhibition by RTP and RDP but not RMP.\",\n      \"method\": \"In vitro PARN deadenylase activity kinetic analysis with varied Mg²⁺\",\n      \"journal\": \"Journal of enzyme inhibition and medicinal chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — rigorous kinetic analysis but single lab, single method, in vitro only\",\n      \"pmids\": [\"18763168\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"PARN interacts with polypyrimidine tract-binding protein 1 (PTBP1) in pancreatic β cells, co-regulating the RNA stability of Slc30a8 and Chst3 mRNAs. PARN deficiency in β cells impairs glucose-stimulated insulin secretion (GSIS) and insulin maturation; conditional PARN knockout mice show reduced GSIS without altered β-cell development or insulin sensitivity.\",\n      \"method\": \"β-cell-specific conditional Parn KO mice, co-immunoprecipitation of PARN with PTBP1, LACE-seq for RNA-protein interactions, NIT-1 cell knockdown, glucose-stimulated insulin secretion assay, transcriptomics\",\n      \"journal\": \"Advanced science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional KO model combined with co-IP and RNA-protein interaction sequencing, single lab\",\n      \"pmids\": [\"39297407\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"In glioblastoma stem cells, PARN positively regulates EGFR expression by negatively regulating the EGFR-targeting miRNA miR-7 through its 3'-5' exoribonuclease activity. Increased EGFR then creates a positive feedback loop activating STAT3, which transcriptionally drives PARN expression. PARN depletion in GSCs reduces tumor infiltration and prolongs survival in orthotopic xenografts.\",\n      \"method\": \"PARN knockdown (siRNA, shRNA), miR-7 level measurement, EGFR/STAT3 signaling assays, orthotopic brain tumor xenograft survival, pharmacological STAT3 inhibition, siRNA nanocapsule delivery\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function with in vivo xenograft and signaling epistasis, single lab\",\n      \"pmids\": [\"37747775\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"PARN binds 3' UTRs and promotes utilization of proximal poly(A) sites genome-wide in B cells in vivo, binding UGUA and AA(U/A)AAA upstream elements to form a specific spatial RNA-protein complex. Through its exonuclease activity, PARN shortens poly(A) tails to decrease mRNA stability of targets including Foxp1, thereby promoting antibody secretion and class switch recombination.\",\n      \"method\": \"Conditional B-cell PARN knockout, genome-wide poly(A) site sequencing, RNA immunoprecipitation for binding elements, poly(A) tail length analysis, antibody secretion assay\",\n      \"journal\": \"Advanced science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional KO with genome-wide poly(A) site sequencing and functional antibody secretion readout, single lab\",\n      \"pmids\": [\"42118147\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"PARN associates with pri-miR-29a and pri-miR-1207 and regulates their poly(A) tail lengths. CPSF6 recruits PARN to pri-miRNAs, and together they affect primary and mature miR-29a-3p levels. miR-29a-3p and miR-1207-5p in turn bind the 3' UTR of PARN mRNA to regulate its expression, establishing a mutual feedback regulatory loop. Modulation of PARN, miR-29a-3p, or miR-1207-5p expression affects cell migration.\",\n      \"method\": \"RNA immunoprecipitation of PARN with pri-miRNAs, CPSF6 co-immunoprecipitation, 3' UTR reporter for PARN mRNA, miRNA 3'-end sequencing, migration assay\",\n      \"journal\": \"Life science alliance\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RNA-IP plus reporter assays plus functional migration readout, single lab\",\n      \"pmids\": [\"41825960\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"PARN is a divalent metal ion-dependent, poly(A)-specific 3'-to-5' exoribonuclease that functions as an obligate homodimer (with dimerization required for activity) and simultaneously engages the mRNA 5' cap (via its cap-binding domain) and the 3' poly(A) tail to processively deadenylate mRNAs; it also localizes to nucleoli and Cajal bodies where it removes PAPD5-added oligo(A) tails from H/ACA snoRNAs, scaRNAs, TERC, Y RNAs, and certain miRNAs—preventing their degradation by EXOSC10 and DIS3L/DIS3L2—and its activity is regulated by phosphorylation (e.g., MK2-mediated Ser557 phosphorylation that shifts PARN from ER to cytosol or expels CBP80 from the nucleolus to relieve inhibition), by RNA-binding protein co-factors (CUG-BP/CUGBP1, nucleolin, Ago2-miRISC) that recruit it to specific substrates, and by its own oligomerization state, collectively controlling mRNA stability, ncRNA maturation, telomere maintenance, ribosome biogenesis, and p53 levels.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"PARN is a divalent metal ion-dependent, poly(A)-specific 3'-to-5' exoribonuclease that controls the stability and 3'-end maturation of both mRNAs and small noncoding RNAs [#0, #1, #3]. Structurally it functions as an obligate homodimer in which the R3H domain of one subunit partially encloses the catalytic site of the other, and disrupting dimerization abolishes both nuclease and RNA-binding activity [#0]; the enzyme can further self-associate into tetramers and higher-order oligomers that enhance catalytic processivity [#19]. PARN simultaneously engages the substrate 3' poly(A) tail and the mRNA 5' cap, and cap binding amplifies its processive deadenylation [#0, #14, #16]. In the nucleolus and Cajal bodies, PARN performs maturation trimming by removing oligo(A) tails that the noncanonical poly(A) polymerase PAPD5 adds to H/ACA box snoRNAs, scaRNAs, the telomerase RNA TERC/hTR, and Y RNAs; without PARN these oligoadenylated species are diverted to exonucleolytic destruction by EXOSC10/RRP6 or DIS3L/DIS3L2, so PARN stabilizes these RNAs by preventing their degradation [#3, #4, #5, #8, #10]. Through analogous removal of PAPD5-added oligo(A) tails, PARN also destabilizes specific miRNAs, including a set that represses p53 translation, so that PARN loss elevates p53 in a Dicer-dependent manner [#7]. PARN substrate selection is directed by RNA-binding cofactors—CUGBP1, nucleolin, Ago2-miRISC, PTBP1, and CPSF6—that recruit it to defined transcripts such as c-fos, TNFα, miR-122, and TP53 mRNA [#2, #6, #17, #18, #25, #28], and its activity is gated by phosphorylation, including DNA-damage/MK2-driven Ser557 phosphorylation that switches its localization and partner selection between the nucleolus, ER, and cytosol [#15, #21]. Biallelic PARN mutations reduce deadenylase activity, shorten telomeres, and perturb snoRNA processing and ribosome biogenesis, with effects on hematopoiesis and embryonic development [#12, #20].\",\n  \"teleology\": [\n    {\n      \"year\": 2001,\n      \"claim\": \"Established that PARN is a poly(A)-specific 3' exonuclease whose poly(A) binding contributes to substrate specificity and that can act in the nucleus, defining the basic enzymatic identity.\",\n      \"evidence\": \"Protein purification, in vitro deadenylation, and Xenopus oocyte microinjection of xPARN\",\n      \"pmids\": [\"11424938\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of poly(A) recognition not yet resolved\", \"Human enzyme regulation not addressed\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Resolved how PARN catalysis works structurally, showing the active unit is a homodimer in which the R3H domain of one subunit engages the partner active site and cap binding amplifies processivity.\",\n      \"evidence\": \"X-ray crystallography of free and RNA-bound truncated human PARN plus dimerization-disrupting mutagenesis\",\n      \"pmids\": [\"16281054\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"C-terminal domain absent from crystallized construct\", \"Cap-binding domain mechanism not directly visualized\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Answered how PARN is targeted to specific mRNAs, identifying CUGBP1 as the first RNA-binding protein that directly recruits a deadenylase to ARE-containing substrates.\",\n      \"evidence\": \"In vitro deadenylation, co-IP from extracts, and recombinant protein pulldown on c-fos/TNFα mRNAs\",\n      \"pmids\": [\"16601207\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo significance of CUGBP1 recruitment not established\", \"Generality across other ARE mRNAs untested\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Extended PARN's role from mRNA decay to noncoding RNA maturation, showing it trims PAPD5-added oligo(A) tails to complete 3'-end maturation of H/ACA snoRNAs and scaRNAs in nucleoli and Cajal bodies.\",\n      \"evidence\": \"siRNA knockdown with 3'-end deep sequencing, immunofluorescence, and PAPD5 epistasis; parallel mouse myoblast mRNA stability/migration study\",\n      \"pmids\": [\"22442037\", \"22956911\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Why C/D box snoRNAs are spared not explained\", \"Direct enzyme-substrate kinetics in vivo not measured\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Connected PARN to telomere biology and disease by showing it matures TERC by removing oligo(A) tails, with patient mutations reducing TERC and shortening telomeres while broadening the miRNA/mRNA targets directed by CUGBP1 and miRISC.\",\n      \"evidence\": \"TERC 3'-end sequencing in patient cells with complementation rescue; PARN/CUGBP1 reconstitution on miR-122; Ago2-PARN co-IP and TP53 3'-UTR reporters; patient cell activity assays with zebrafish/marrow knockdown\",\n      \"pmids\": [\"26482878\", \"26130707\", \"26400160\", \"26342108\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Causal chain from TERC defect to specific clinical phenotypes incompletely mapped\", \"Several cofactor recruitment events from single labs\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Defined the degradation pathways PARN protects against, showing PARN-mediated deadenylation of hTR limits PAPD5-EXOSC10 decay and decapping/XRN1 routes, and characterized the cap-binding mechanism biophysically.\",\n      \"evidence\": \"Multi-component knockdown epistasis (PAPD5, EXOSC10, DCP2, XRN1) with telomerase assays; SPR/fluorescence/CD cap-binding kinetics\",\n      \"pmids\": [\"26950371\", \"26772900\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry of competing decay enzymes in cells not quantified\", \"Physiological cap forms engaged in vivo unclear\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Broadened the noncoding RNA target set and revealed cofactor-controlled activation, establishing Y RNA stabilization via PAPD5/DIS3L and nucleolin phosphorylation as an activating switch for PARN.\",\n      \"evidence\": \"PARN/PAPD5/DIS3L knockdown epistasis with 3'-end sequencing; NCL-PARN co-IP and deadenylase assays with phospho-deficient NCL under UV stress\",\n      \"pmids\": [\"28760775\", \"29168431\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab findings without reciprocal validation\", \"Kinase responsible for NCL phosphorylation in this context not pinned down\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Clarified the division of labor among nuclear trimming enzymes, showing PARN acts redundantly with TOE1 on scaRNAs/TERC and works downstream of RRP6 in a two-step TERC processing pathway guided by H/ACA RNP assembly.\",\n      \"evidence\": \"PARN/TOE1 double knockdown with mTAIL-seq and snRNA pseudouridylation; in vitro processing with purified PARN and RRP6 plus RNP assembly and structure probing\",\n      \"pmids\": [\"29669292\", \"30575725\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Determinants partitioning a precursor to processing vs degradation only partly defined\", \"Redundancy quantification incomplete\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Linked PARN to p53 control and organismal phenotypes, showing it destabilizes p53-repressing miRNAs via DIS3L/DIS3L2, that a phospho-mimic C-terminal switch reshapes nucleolar partner selection, and that PARN loss impairs rRNA biogenesis with embryonic lethality in mice.\",\n      \"evidence\": \"PARN/PAPD5/DIS3L/DIS3L2 knockdown with miRNA sequencing and Dicer-dependence; S557D mutagenesis with CTD spectroscopy, imaging, and CBP80/CstF-50 co-IP; patient fibroblasts, heterozygous and homozygous Parn KO mice\",\n      \"pmids\": [\"30770239\", \"31387300\", \"31273937\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Some mechanistic links inferred from expression data\", \"Identity of the S557 kinase under DNA damage not defined here\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Revealed compartmentalized PARN function, showing ER-anchored PARN shapes ER-associated transcript poly(A) profiles and that MK2 phosphorylation of Ser557 drives its DNA-damage relocalization from ER to cytosol.\",\n      \"evidence\": \"Subcellular fractionation, liposome insertion of purified PARN, ER-anchored constructs, ER-RNA transcriptomics, and MK2 phosphorylation assay\",\n      \"pmids\": [\"31936572\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab study; mechanism of ER anchoring partly inferred\", \"Generality of ER pool beyond tested transcripts unknown\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Demonstrated a disease-relevant feedforward circuit, with PARN sustaining EGFR by degrading miR-7 to drive STAT3-dependent PARN expression and tumor infiltration in glioblastoma stem cells.\",\n      \"evidence\": \"PARN knockdown, miR-7/EGFR/STAT3 assays, and orthotopic xenograft survival with STAT3 inhibition\",\n      \"pmids\": [\"37747775\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Directness of PARN action on miR-7 vs indirect effects not fully separated\", \"Single tumor model\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Extended PARN to metabolic physiology, showing it partners with PTBP1 to regulate Slc30a8/Chst3 mRNA stability and is required for glucose-stimulated insulin secretion.\",\n      \"evidence\": \"β-cell conditional Parn KO mice, PARN-PTBP1 co-IP, LACE-seq, and GSIS assays\",\n      \"pmids\": [\"39297407\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether deadenylation per se underlies the secretion phenotype not fully isolated\", \"Single lab\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Showed PARN acts on poly(A) site choice and miRNA biogenesis in vivo, promoting proximal poly(A) usage and Foxp1 destabilization in B cells, and forming a mutual feedback loop with miR-29a/miR-1207 via CPSF6 recruitment.\",\n      \"evidence\": \"Conditional B-cell Parn KO with genome-wide poly(A) sequencing and antibody assays; PARN/CPSF6 co-IP, pri-miRNA RIP, and PARN 3'-UTR reporters with migration assays\",\n      \"pmids\": [\"42118147\", \"41825960\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism coupling deadenylation to poly(A) site selection unresolved\", \"Single-lab findings awaiting independent replication\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the many cofactor-recruitment and phosphorylation inputs are integrated to direct PARN between its mRNA-decay, ncRNA-maturation, and compartment-specific functions in a given cell state remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model integrating cofactor selection with localization switching\", \"Quantitative substrate hierarchy in vivo not established\", \"Kinase network controlling PARN phosphosites incompletely mapped\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140098\", \"supporting_discovery_ids\": [0, 1, 3, 7, 8, 19]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [0, 1, 24]},\n      {\"term_id\": \"GO:0003723\", \"supporting_discovery_ids\": [0, 1, 14, 16, 27, 28]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005730\", \"supporting_discovery_ids\": [3, 15]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [1, 15]},\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [21]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [21]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-8953854\", \"supporting_discovery_ids\": [3, 4, 7, 8, 10]},\n      {\"term_id\": \"R-HSA-1852241\", \"supporting_discovery_ids\": [12, 20]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"PAPD5\", \"CUGBP1\", \"NCL\", \"AGO2\", \"PTBP1\", \"CPSF6\", \"CBP80\", \"DKC1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}